Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors

• Published in: Annals of hematology 2017-10, Vol.96 (10), p.1735-1739
• Main Authors: Farhan, Roiya, Urbanowska, Elżbieta, Zborowska, Hanna, Król, Małgorzata, Król, Maria, Torosian, Tigran, Piotrowska, Iwona, Bogusz, Krzysztof, Skwierawska, Kamila, Wiktor-Jędrzejczak, Wiesław, Snarski, Emilian
• Format: Article
• Language: English
• Subjects: Adult; Biosimilar Pharmaceuticals - administration & dosage; Female; Filgrastim - administration & dosage; Granulocyte Colony-Stimulating Factor - administration & dosage; Hematology; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original; Original Article; Recombinant Proteins - administration & dosage; Stem cells; Tissue Donors
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-017-3060-4

The World Marrow Donor Organization recommends original granulocyte-colony stimulating factor (G-CSF) for the mobilization of stem cells in healthy unrelated hematopoietic stem cell donors. We report the comparison of a biosimilar G-CSF (Zarzio) with two original G-CSFs (filgrastim and lenograstim) in mobilization in unrelated donors. We included data of 313 consecutive donors who were mobilized during the period from October 2014 to March 2016 at the Medical University of Warsaw. The primary endpoints of this study were the efficiency of CD34+ cell mobilization to the circulation and results of the first apheresis. The mean daily dose of G-CSF was 9.1 μg/kg for lenograstim, 9.8 μg/kg for biosimilar filgrastim, and 9.3 μg/kg for filgrastim ( p